Ann Lab Med.  2024 May;44(3):193-194. 10.3343/alm.2023.0467.

Toward Standardization of Flow-Cytometric Immunophenotyping for the Diagnosis and Monitoring of Hematologic Malignancies

• Kim SY
• Huh HJ

• KMID: 2555682
• DOI: http://doi.org/10.3343/alm.2023.0467

Keyword

Flow cytometry; Hematologic malignancies; Immuno phenotyping

Reference

References

1. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. 2022; Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 140:1345–77. DOI: 10.1182/blood.2022016867. PMID: 35797463.

2. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. 2022; The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 36:1720–48. DOI: 10.1038/s41375-022-01620-2. PMID: 35732829. PMCID: PMC9214472.

3. Park JH, Choi HW, Shin MG. 2022; Coexistence of acute promyelocytic leukemia and primary plasma cell leukemia: careful consideration in diagnosis. Ann Lab Med. 42:278–81. DOI: 10.3343/alm.2022.42.2.278. PMID: 34635620. PMCID: PMC8548240.

4. Lee B, Lim DJ, Heo WY, Yoon SE, Kim HY, Kim HJ, et al. 2021; Aberrant loss of surface CD3 and TCRγδ expression in relapsed hepatosplenic T-cell lymphoma. Ann Lab Med. 41:598–600. DOI: 10.3343/alm.2021.41.6.598. PMID: 34108288. PMCID: PMC8203428.

5. Kim HJ, You E, Hong S, Park CJ. 2021; A case of IgG4-related disease with bone marrow involvement: bone marrow findings and flow cytometric immunophenotyping of plasma cells. Ann Lab Med. 41:243–6. DOI: 10.3343/alm.2021.41.2.243. PMID: 33063688. PMCID: PMC7591282.

6. Park SH, Lee YJ, Kim Y, Kim HK, Lim JH, Jo JC. 2023; T-large granular lymphocytic leukemia. Blood Res. 58:S52–7. DOI: 10.5045/br.2023.2023037. PMID: 37026382. PMCID: PMC10133854.

7. Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, et al. 2017; Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 129:347–57. DOI: 10.1182/blood-2016-07-726307. PMID: 27903527. PMCID: PMC5291958.

8. Kim HY, Yoo IY, Lim DJ, Kim HJ, Kim SH, Yoon SE, et al. 2022; Clinical utility of next-generation flow-based minimal residual disease assessment in patients with multiple myeloma. Ann Lab Med. 42:558–65. DOI: 10.3343/alm.2022.42.5.558. PMID: 35470273. PMCID: PMC9057816.

9. Riva G, Nasillo V, Ottomano AM, Bergonzini G, Paolini A, Forghieri F, et al. 2021; Multiparametric flow cytometry for MRD monitoring in hematologic malignancies: clinical applications and new challenges. Cancers (Basel). 13:4582. DOI: 10.3390/cancers13184582. PMID: 34572809. PMCID: PMC8470441.

10. Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Böttcher S, Ritgen M, et al. 2012; EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 26:1986–2010. DOI: 10.1038/leu.2012.122. PMID: 22948490. PMCID: PMC3437409.

11. Park M, Lim J, Ahn A, Oh EJ, Song J, Kim KH, et al. 2024; Current status of flow-cytometric immunophenotyping of hematolymphoid neoplasms in Korea. Ann Lab Med. 44:222–34. DOI: 10.3343/alm.2023.0298. PMID: 38145891.